AgomAb Therapeutics NV ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
76.1%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$2.07next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| STENOVA Open-Label Extension (OLE) Topline Data Readout | 31 Dec 2026 |
| AGMB-447 Phase 1b IPF Cohort Topline Data Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Ontunisertib (AGMB-129) Phase 2b NOV-ERA Study Initiation AnnuallyTarget: First participant dosed in the second half of 2026
AGMB-447 Phase 2 Study Initiation in Idiopathic Pulmonary Fibrosis (IPF) AnnuallyTarget: Study initiation in the second half of 2026
Cash Runway QuarterlyTarget: Fund operations into the first half of 2029
Watch Items
- Ontunisertib (AGMB-129) Open-Label Long-Term Extension (OLE) STENOVA DataTrigger: Topline 48-week safety and efficacy data readoutAction: Evaluate long-term safety profile and potential for sustained efficacy to support Phase 2b/3 development
- AGMB-447 Phase 1b IPF Cohort DataTrigger: Topline safety, tolerability, and pharmacokinetic data readoutAction: Confirm lung-restricted exposure and safety in patients to validate progression to Phase 2
Research as of 24 Jul 2026